Skip to content
PepFinder

Peptides for healing and recovery: what the research shows

Peptides for healing and recovery is a marketing category, not a medical one. The five peptides most often sold under it, BPC-157, TB-500, GHK-Cu, KPV and LL-37, have been studied mainly in rats, mice and cell cultures. The only controlled human trials in this group tested creams or gels on skin ulcers, using GHK-Cu or LL-37. None of these peptides is an approved medicine, and no trial has tested them for sports injuries, muscle recovery or joint pain.

By the PepFinder editorial team · Reviewed 24 Sept 2026 · Editorial independence

Compare prices: peptides for healing and recovery

Lowest single-vial price at any size and how many stores list each one, from listings re-checked daily. Prices are shown in your region’s currency and never converted. A price is not a recommendation to use any of these compounds.

BPC-157

138 stores
  • 2mg
  • 5mg
  • 10mg
  • 20mg

FromUS$13.88

Compare →

GHK-Cu

136 stores
  • 50mg
  • 100mg
  • 200mg

FromUS$14.99

Compare →

TB-500

127 stores
  • 2mg
  • 5mg
  • 10mg
  • 20mg

FromUS$16.59

Compare →

KPV

103 stores
  • 5mg
  • 10mg

FromUS$23.99

Compare →

LL-37

56 stores
  • 5mg
  • 10mg

FromUS$34.99

Compare →
Peptides for healing and recovery: side by side
 Studied forMain evidenceHuman dataStatus
BPC-157Tendon, ligament, muscle, bone and gut injuryRat injury models, most from one Zagreb group [1] [6]Three small uncontrolled pilot reports, about 30 people in total [7]Not approved; FDA safety-risk list, since withdrawn [41]; WADA S0 [43]
TB-500Tendon repair and skin woundsOne 2026 rat Achilles study [11]; wound work mostly used full-length thymosin beta-4 [16]None for TB-500; trials used full-length thymosin beta-4 [18]Not approved; FDA safety-risk list, since withdrawn [41]; WADA S2 [43]
GHK-CuSkin wounds and skin repairCell collagen studies and rat wound studies [27] [29]One 1994 randomised trial of a gel on diabetic foot ulcers [26]; no trials of injectionCosmetic ingredient; not an approved medicine; injectable form on FDA list, since withdrawn [41]
KPVGut and skin inflammationMouse colitis models and cell studies [22] [23]None publishedNot approved; FDA safety-risk list, since withdrawn [41]
LL-37Chronic wounds and infection defenceHuman skin and wound tissue studies [34]Three randomised trials of topical LL-37 on leg or foot ulcers [31] [32] [33]Not approved; FDA safety-risk list, since withdrawn [41]

What healing peptides are, and what they are not

Healing peptides is the label sellers and forums use for a small group of research peptides said to speed repair of tendons, muscles, joints, the gut and the skin. The term has no regulatory meaning. The same five names come up again and again: BPC-157, TB-500, GHK-Cu, KPV and LL-37. Our guide to what research peptides are explains why products sold this way are not medicines, whatever their marketing says.

The five are chemically unrelated. BPC-157 is a synthetic 15-amino-acid peptide based on a protein described in gastric juice. TB-500 is a seven-amino-acid fragment of thymosin beta-4, a protein that binds actin inside cells [14]. GHK-Cu is a copper-bound three-amino-acid peptide found naturally in blood. KPV is the last three amino acids of the hormone alpha-MSH. LL-37 is the body's own antimicrobial peptide, made by white blood cells and skin cells. They have been grouped together because of how they are marketed, not because they share a mechanism.

The evidence behind them also differs in kind. For BPC-157, TB-500 and KPV almost everything comes from animals and cells. For GHK-Cu and LL-37 there are small human trials, but they applied the peptide to open wounds rather than injecting it. When people search for recovery peptides or peptides for recovery, they usually mean injected products for sports injuries or training recovery. That use has no controlled human trial behind it for any of the five. The sections below go through each goal and say which species and which formulation each result came from.

Peptides for tendon repair and injury recovery

Most searches for peptides for injury recovery and peptides for tendon repair lead to BPC-157 and TB-500. The best-known BPC-157 experiment is a 2003 rat study in which the Achilles tendon was cut and the animals received daily injections into the abdomen. Treated rats had higher load to failure, better walking scores and more organised healing tissue than controls [1]. In rat tendon cells, BPC-157 did not make the cells divide faster, but it helped them survive oxidative stress and move, through the FAK–paxillin pathway [2]. It also increased blood-vessel growth in laboratory models through the VEGFR2 receptor [3].

These results come mostly from one research group at the University of Zagreb. A 2025 systematic review found 36 studies of BPC-157 in orthopaedic sports medicine, of which 35 were preclinical, and graded the evidence as level IV and V, the lowest levels on its scale. It found no clinical safety data [6]. A 2025 narrative review from the University of Utah reached a similar view: broad animal support, extremely limited human data, and a recommendation that BPC-157 be treated as investigational [7].

For TB-500 the direct evidence is thinner. Most of the wound and repair studies people cite used full-length thymosin beta-4, a 43-amino-acid protein, not the seven-amino-acid fragment that is sold [16]. A 2003 mouse study found that the fragment's core sequence promoted skin repair in aged mice [15]. The first independent test on tendon came in 2026, when a group in Istanbul cut and repaired the Achilles tendons of 32 rats and gave BPC-157, TB-500, both, or nothing for four weeks. TB-500 gave a significantly higher load to failure than controls; BPC-157 gave better tissue scores that did not reach statistical significance for the totals [11]. That result for BPC-157 was weaker than the Zagreb reports.

There are no controlled human trials of either peptide for tendon or ligament injury. A 2026 scoping review in the American Journal of Sports Medicine, covering BPC-157, TB-500, GHK-Cu and three other peptides, found that two-thirds of the publications used animal models and concluded that claimed musculoskeletal benefits are not supported by current human trials [21]. A 2026 Sports Medicine review reached the same conclusion: favourable animal results, scarce rigorous human safety data [20].

Peptides for muscle recovery

Searches for peptides for muscle recovery usually mean recovering faster from training. No study has tested any of these five peptides for that. What exists is research on repair after a severe injury in rats. In a 2006 study, rats had the quadriceps muscle cut right through and were given daily BPC-157 injections at 10 µg/kg, 10 ng/kg or 10 pg/kg. The authors reported better strength, walking recovery and muscle fibre regeneration over 72 days [4]. A 2021 study from the same group found similar results when the quadriceps tendon was detached from the muscle, with BPC-157 given by injection or in drinking water [5].

These are models of a surgically severed muscle, not of the soreness and small-scale damage that follow exercise. We found no study of BPC-157 in healthy, uninjured animals or people training for sport. The TB-500 guide makes the same point: claims that TB-500 speeds recovery from training have no published support in animals or people. Neither GHK-Cu, KPV nor LL-37 has been studied for muscle at all. A 2026 primer for orthopaedic and sports medicine doctors noted that no clinical data support GHK-Cu for musculoskeletal conditions and that dosing, frequency and duration are unknown [30].

Peptides for joint pain

The only human report on peptides for joint pain in this group is a 2021 retrospective chart review from a private clinic in Florida. It looked back at 16 people who had received knee injections. Of 12 given BPC-157 alone, 11 were reported to have significant improvement in pain; four others received BPC-157 with thymosin beta-4 [8]. Pain was assessed by telephone survey months later, with no validated scoring tool, no control group and no blinding. A later systematic review summarised the same study as 7 of 12 people reporting relief lasting more than six months, which shows how loosely the outcome was defined [6].

That report cannot show that BPC-157 relieves knee pain, because knee pain often improves on its own and with other treatment. No randomised trial of BPC-157, TB-500, GHK-Cu, KPV or LL-37 for arthritis, cartilage damage or joint pain has been published. A small randomised pilot of BPC-157 after rotator cuff surgery was registered in 2026 and was listed as not yet recruiting when we checked.

Peptides for gut health

Two of the five are sold as peptides for gut health. BPC-157 was first described as a fragment of a protein found in gastric juice, and its discoverers studied it first as a stomach-protective agent. A 2012 review by the originating group described it as stable in human gastric juice and summarised rat work on colitis, bowel surgery and fistulas [12]. In one rat study, BPC-157 given in drinking water or by injection healed chemically induced colitis and helped join two cut ends of colon [13]. The review said BPC-157 had been tested in phase II trials for inflammatory bowel disease under the code PL 14736 [12], but we could not find published results.

KPV has a different route into the gut. It is carried into intestinal cells by a transporter called PepT1, which is increased in the inflamed colon. In a 2008 study, KPV in drinking water reduced inflammation in two chemical models of colitis in mice, and nanomolar concentrations damped inflammatory signalling in human intestinal cells [22]. A second 2008 study found that KPV sped recovery in mouse colitis and rescued mice lacking a working melanocortin-1 receptor from death during colitis [23].

Neither peptide has a published human trial for any gut condition, including ulcerative colitis, Crohn's disease, reflux or irritable bowel syndrome. No study has compared them directly. Our KPV vs BPC-157 comparison sets the two side by side.

Peptides for inflammation

All five peptides are promoted as peptides for inflammation, but the evidence points in different directions. KPV is the most directly anti-inflammatory in the laboratory. In a 2003 mouse study of inflammation in the abdominal lining, it reduced the build-up of white blood cells, and its effect was not blocked by a melanocortin receptor antagonist [24]. In human airway cells it reduced the release of inflammatory chemokines by interfering with the NF-κB signalling pathway [25]. These are cell and mouse findings; KPV has no published human data.

BPC-157 reviews describe reduced inflammatory signalling in animal models, but this has not been measured in people [7]. GHK-Cu lowered the inflammatory marker TNF-alpha in rat wounds [27]. LL-37 is the odd one out. It is part of the immune response, and too much of it is linked to inflammatory skin disease. A 2007 Nature study found that LL-37 turns the body's own DNA into a trigger for immune activation, a pathway proposed to drive psoriasis [35]. Another 2007 study found abnormally high levels of cathelicidin in the skin of people with rosacea and showed that these peptides increased skin inflammation in mice [36]. LL-37 is therefore better described as an immune signal than as an anti-inflammatory.

Wound healing and skin: GHK-Cu and LL-37

This is where the human evidence is strongest, and it concerns topical use on wounds. In a 1994 multicentre, randomised, placebo-controlled trial in people with diabetic foot ulcers, all of whom also received standard wound care, a daily GHK-Cu gel increased median closure of plantar ulcers to 98.5%, compared with 60.8% for the gel alone. Infections were less common in the treated group [26]. GHK-Cu did not go on to become an approved treatment. In rats, a 2% GHK-Cu gel shrank wounds with a reduced blood supply faster than the gel base [27], but a 2013 rat study of irradiated skin flaps found no benefit [28]. In fibroblast cultures GHK-Cu stimulated collagen production [29].

LL-37 has the most human trial data of the five. A 2003 study found that its precursor rises sharply in human skin after wounding and is missing from the edge of chronic leg ulcers; blocking LL-37 stopped cultured human skin from re-covering a wound [34]. In a first trial in 34 people with hard-to-heal venous leg ulcers, the two lower strengths of LL-37 applied to the wound were associated with faster healing than placebo, while the highest strength was no better than placebo [31]. A larger phase 2b trial in 148 patients found no significant improvement in healing overall [32]. A randomised trial in people with mildly infected diabetic foot ulcers found more healthy granulation tissue with LL-37 cream, but no reduction in inflammatory markers or bacterial counts [33].

Full-length thymosin beta-4, the parent of TB-500, has also been tested on skin. In rats it sped the re-covering of wounds by up to 61% over saline at seven days [16], and in a phase 2 trial of 73 people with venous leg ulcers a topical gel had a safety profile similar to placebo, with the authors suggesting one strength may have the potential to speed healing [19]. None of these results applies to injected TB-500. A 2024 study found that TB-500 itself did not improve wound closure in cultured cells, while one of its breakdown products did [17].

The gap between this evidence and how the peptides are sold is large. Every human wound trial used a cream, gel or solution on an open wound. Research-peptide vials are sold for injection, which none of the trials tested.

The Wolverine stack: BPC-157 and TB-500 together

The wolverine stack is an online nickname for BPC-157 and TB-500 used together, sold either as two vials or as one pre-mixed blend. The idea is that the two act by different routes, blood-vessel growth from BPC-157 and cell migration from TB-500, so their effects might add up. That is a hypothesis built from separate studies of each molecule.

Only one controlled study has tested the combination: the 2026 rat Achilles study. Rats given both peptides did no better than those given either one alone, and the authors reported that combining them did not confer additional benefits [11]. The only human data involving both come from the knee chart review, in which four people received BPC-157 with thymosin beta-4, too few to show anything [8]. No study has tested a pre-mixed blend, a combined dose, or whether the two peptides stay stable in one vial. Everything published on the pair is collected on our BPC-157 and TB-500 page, and three- and four-peptide blends that add GHK-Cu or KPV are covered in Glow and Klow peptide blends.

Doses used in published research

This section reports what studies used. It is not guidance, and animal doses should not be converted to human doses. In rats, BPC-157 was usually given at 10 µg/kg a day by injection into the abdomen [1] [11], and TB-500 at 60 µg/kg a day in the 2026 tendon study [11]. KPV was given to mice in drinking water [22].

In people, the BPC-157 pilot reports used 10 mg injected into the bladder wall in one procedure in a study of interstitial cystitis [9], and 10 mg then 20 mg by intravenous infusion in a two-person safety study [10]. Full-length thymosin beta-4 was given intravenously at 42 mg to 1,260 mg in a phase 1 trial [18], a different, much larger molecule from TB-500. LL-37 was applied to leg ulcers at 0.5, 1.6 or 3.2 mg/mL twice a week, and the highest strength worked no better than placebo [31]. The GHK-Cu ulcer trial used a daily topical gel [26]. No controlled trial has established a human dose of any of these peptides for injection.

Converting a vial's stated contents into a concentration is arithmetic, not dosing, and our peptide calculator does that sum. It assumes the vial contains what its label says, and it does not tell anyone what amount, if any, is appropriate.

Side effects, product quality and unknowns

The small BPC-157 pilot reports described no adverse events, but they involved about 30 people with short follow-up [8] [9] [10]. There are no human safety data for TB-500 or KPV. Topical GHK-Cu and topical LL-37 were well tolerated in their wound trials [26] [31] [32]. Injected LL-37 is less reassuring: a patient in a melanoma trial developed multiple wart-like and blistering skin lesions after eight weekly injections into tumours, which cleared after the injections stopped [37].

Cancer is an open question rather than an observed effect. BPC-157 promotes blood-vessel growth in the laboratory [3], thymosin beta-4 is found at higher levels in some tumours (see the TB-500 guide), and high LL-37 levels have been linked with the growth of ovarian, lung and breast cancers but with suppression of tumours in the colon and stomach [38]. A 2026 review of unregulated injectable peptides listed pathological blood-vessel growth and cancer among the potential risks of BPC-157, TB-500 and similar products [40]. No study has tested whether any of these peptides starts or speeds a cancer in people.

Product quality is a documented problem. French anti-doping researchers found that products sold online as TB500 and TB1000 did not consistently match their descriptions [39]. Pre-mixed blends add another unknown, because the label cannot show how much of each peptide is present. Independent testing is the only way to check contents; see third-party peptide testing.

Sport and regulatory status

None of the five is an approved medicine. In the US, the FDA placed BPC-157, TB-500, KPV, LL-37 and injectable GHK-Cu in category 2 of its compounding policy, the list of bulk substances that may present significant safety risks, citing concerns including immune reactions and peptide-related impurities. The nominations were later withdrawn, and the FDA now lists them among substances previously in category 2. Withdrawal is not an authorisation [41]. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee considered BPC-157, TB-500 and KPV for the list of substances US pharmacies may compound under section 503A; the FDA had posted no outcome and had not acted when we checked [42].

For athletes, WADA lists BPC-157 under S0 (non-approved substances) and thymosin beta-4 and its derivatives, including TB-500, under S2, so both are prohibited at all times, as is any blend containing either [43]. We have not confirmed the WADA status of KPV or LL-37. A Health Canada advisory in April 2026 named BPC-157, TB-500, GHK-Cu and KPV among seized unauthorised peptides and said research-use labelling does not make them legal [44]. National rules are on our legal status pages, including the UK.

Comparing prices and suppliers

PepFinder tracks listings for each peptide on this page: BPC-157 prices, TB-500 prices, GHK-Cu prices, KPV prices and LL-37 prices. Blends such as the Wolverine stack are usually listed under one of their ingredients. When comparing a blend with separate vials, compare the price per milligram of each peptide, not the price per vial.

Price is only part of the picture for unregulated products. Our guide on how to read a peptide COA explains what a certificate of analysis should show, and how to spot a fake peptide supplier lists common warning signs. We also list third-party tested suppliers. A listing on PepFinder does not mean a product is legal to buy where you live, or that it is suitable for human use.

Full guides and prices

References

  1. [1] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PubMed 14554208
  2. [2] Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PubMed 21030672
  3. [3] Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PubMed 27847966
  4. [4] Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006. PubMed 16609979
  5. [5] Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PubMed 34829776
  6. [6] Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PubMed 40756949
  7. [7] McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PubMed 40789979
  8. [8] Lee E, Padgett B Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. PubMed 34324435
  9. [9] Lee E, Walker C, Ayadi B Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. PubMed 39325560
  10. [10] Lee E, Burgess K Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PubMed 40131143
  11. [11] Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PubMed 42542926
  12. [12] Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012. PubMed 22300085
  13. [13] Klicek R, Kolenc D, Suran J, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013. PubMed 24304574
  14. [14] Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PubMed 22962027
  15. [15] Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. PubMed 12581423
  16. [16] Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed 10469335
  17. [17] Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024. PubMed 38382158
  18. [18] Ruff D, Crockford D, Girardi G, Zhang Y A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PubMed 20536472
  19. [19] Guarnera G, DeRosa A, Camerini R The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. PubMed 20536470
  20. [20] Mendias CL, Awan TM Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance Sports Medicine. 2026. PubMed 41966639
  21. [21] Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. PubMed 42578445
  22. [22] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PubMed 18061177
  23. [23] Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PubMed 18092346
  24. [24] Getting SJ, Schiöth HB, Perretti M Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003. PubMed 12750433
  25. [25] Land SC Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012. PubMed 22837805
  26. [26] Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994. PubMed 17147644
  27. [27] Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003. PubMed 14648529
  28. [28] Parker NP, Ardeshirpour F, Schmechel SC, Lassig AA Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngol Head Neck Surg. 2013. PubMed 23744835
  29. [29] Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PubMed 3169264
  30. [30] Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PubMed 41476424
  31. [31] Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014. PubMed 25041740
  32. [32] Mahlapuu M, Sidorowicz A, Mikosinski J, et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen. 2021. PubMed 34687253
  33. [33] Miranda E, Bramono K, Yunir E, et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res. 2023. PubMed 37480520
  34. [34] Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003. PubMed 12603850
  35. [35] Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007. PubMed 17873860
  36. [36] Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007. PubMed 17676051
  37. [37] Dolkar T, Trinidad CM, Nelson KC, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018. PubMed 29665030
  38. [38] Piktel E, Niemirowicz K, Wnorowska U, et al. The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz). 2016. PubMed 26395996
  39. [39] Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023. PubMed 36482504
  40. [40] Moiz A, O'Keefe EL, O'Keefe JH Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs. Mo Med. 2026. PubMed 42757290
  41. [41] US Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page last updated 22 April 2026). FDA. 2026. Source
  42. [42] US Food and Drug Administration July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA. 2026. Source
  43. [43] World Anti-Doping Agency The Prohibited List (2026): S0 Non-Approved Substances and S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA. 2026. Source
  44. [44] Health Canada Think twice before injecting peptides bought online: unauthorized products can seriously harm your health (9 April 2026). Government of Canada Recalls and Safety Alerts. 2026. Source

Frequently asked questions

What are the best peptides for healing?

No peptide has been shown in controlled human trials to speed healing of injuries when injected. BPC-157 and TB-500 have the most animal research for tendon and muscle injury. GHK-Cu and LL-37 have small human trials, but only as creams or gels on skin ulcers.

Do recovery peptides work in humans?

The evidence does not show that they do. BPC-157 has three small uncontrolled human reports, TB-500 and KPV have none, and the human trials of GHK-Cu and LL-37 tested topical products on chronic wounds, not recovery from sport or training.

What are the best peptides for tendon repair?

In rats, BPC-157 and TB-500 have both been reported to improve Achilles tendon healing. In the only study that compared them, TB-500 gave a significant strength advantage and BPC-157 did not. There are no human trials for tendon injury.

Are there peptides for joint pain with human evidence?

Only one uncontrolled report, a retrospective review of 16 people given BPC-157 knee injections with pain assessed by telephone survey. It had no control group, so it cannot show whether BPC-157 relieved pain.

Which peptides are studied for gut health?

BPC-157 and KPV. BPC-157 has been studied in rat models of colitis and bowel surgery, and KPV in mouse colitis. Neither has published human trial results for any gut condition.

What is the Wolverine stack?

It is an online nickname for BPC-157 and TB-500 used together. The one controlled study of the combination, in rats, found no extra benefit over either peptide alone.

Are healing peptides safe?

Their safety in people has not been established. Human safety data are either very small or missing, product quality is inconsistent, and the FDA has raised concerns about immune reactions and impurities for several of them.

Are healing peptides banned in sport?

BPC-157 and TB-500 are prohibited at all times on the WADA Prohibited List, under S0 and S2. We have not confirmed the WADA status of KPV or LL-37.

Are any of these peptides approved medicines?

No. None of BPC-157, TB-500, GHK-Cu, KPV or LL-37 is an approved medicine. GHK-Cu is used in cosmetics as copper tripeptide-1, which covers skin-care products only.

Related

PepFinder is an independent directory. We do not sell peptides, and nothing here is medical advice. Research peptides are not licensed medicines. Suppliers cannot pay to change what we write. Spotted an error? Email editorial@pepfinder.com.